Dr. Antonio Calles 🫁🚭· @Tony_Calles · X·· 13 小时前评分70
正文 · 机器翻译
📖 @sands_jacob 翻开了 SCLC 治疗的新篇章
💥 DeLLphi-305 为 ES-SCLC 患者在诱导化疗-免疫治疗后的维持治疗树立了新的治疗标准
#ESMO26 @myESMO
145 浏览 · 4 赞 · 2 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Dr. Antonio Calles 🫁🚭 · x.com